Apel Daniel Joseph 4
4 · ARROWHEAD PHARMACEUTICALS, INC. · Filed Apr 24, 2026
Research Summary
AI-generated summary of this filing
Arrowhead (ARWR) CFO Daniel Apel Sells 13,095 Shares
What Happened Daniel J. Apel, Chief Financial Officer of Arrowhead Pharmaceuticals (ARWR), sold a total of 13,095 shares in open-market transactions on April 22, 2026, generating approximately $934,286 in proceeds. The sales were reported as three tranches: 3,208 shares at a weighted average price of $70.11 ($224,913), 1,157 shares at $70.45 ($81,511), and 8,730 shares at $71.92 ($627,862). These were dispositions (sales), not purchases.
Key Details
- Transaction date: 2026-04-22; Form 4 filed 2026-04-24 (appears within the standard 2-business-day filing window).
- Tranches and prices:
- 3,208 shares @ $70.11 (weighted avg; actual prices ranged $69.50–$70.23) — $224,913. (Footnote F3)
- 1,157 shares @ $70.45 (weighted avg; actual prices ranged $70.29–$70.51) — $81,511. (Footnote F5)
- 8,730 shares @ $71.92 (weighted avg; actual prices ranged $71.55–$71.97) — $627,862. (Footnote F6)
- Reported total proceeds: ~$934,286.
- Notable footnotes: sales executed pursuant to a pre-established Rule 10b5-1 trading plan (F1); a partial disposition was used to satisfy tax withholding obligations (F2); some shares include previously reported RSU-related shares, a portion of which remain subject to vesting (F4).
- Shares owned after the transaction: not specified in the excerpt provided; see the full Form 4 for updated holdings.
Context
- These were planned sales under a 10b5-1 plan, which typically indicates pre-set instructions rather than discretionary trading at the time of sale—commonly viewed as routine rather than a direct signal about near-term company prospects.
- A portion of the disposition relates to tax withholding for RSUs, which is administrative (not a market-timing purchase or gift).
- No purchases, option exercises, or gifts were reported in this filing.
Insider Transaction Report
Form 4
Apel Daniel Joseph
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1][F2][F3][F4]2026-04-22$70.11/sh−3,208$224,913→ 172,792 total - Sale
Common Stock
[F1][F2][F5][F4]2026-04-22$70.45/sh−1,157$81,511→ 171,635 total - Sale
Common Stock
[F1][F2][F6][F4]2026-04-22$71.92/sh−8,730$627,862→ 162,905 total
Footnotes (6)
- [F1]Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F2]Partial disposition of shares to satisfy tax withholding obligations.
- [F3]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.23, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F4]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
- [F5]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F6]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $71.55 to $71.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Signature
/s/Daniel Joseph Apel|2026-04-24